1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Digna Biotech, S.L. - Product Pipeline Review - 2016

Digna Biotech, S.L. - Product Pipeline Review - 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 38 pages

Digna Biotech, S.L. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Digna Biotech, S.L. - Product Pipeline Review - 2016’, provides an overview of the Digna Biotech, S.L.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Digna Biotech, S.L., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Digna Biotech, S.L.
- The report provides overview of Digna Biotech, S.L. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Digna Biotech, S.L.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Digna Biotech, S.L.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Digna Biotech, S.L.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Digna Biotech, S.L.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Digna Biotech, S.L.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

Digna Biotech, S.L. - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Digna Biotech, S.L. Snapshot 5
Digna Biotech, S.L. Overview 5
Key Information 5
Key Facts 5
Digna Biotech, S.L. - Research and Development Overview 6
Key Therapeutic Areas 6
Digna Biotech, S.L. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Digna Biotech, S.L. - Pipeline Products Glance 13
Digna Biotech, S.L. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Digna Biotech, S.L. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Digna Biotech, S.L. - Drug Profiles 17
Cardiotrophin-1 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
disitertide 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Interferon Alfa-5 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
DB-017 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
DB-02901 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
DB-036 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
DB-039 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
DB-055 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
oncostatin M 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
DB-027 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Digna Biotech, S.L. - Pipeline Analysis 30
Digna Biotech, S.L. - Pipeline Products by Target 30
Digna Biotech, S.L. - Pipeline Products by Route of Administration 31
Digna Biotech, S.L. - Pipeline Products by Molecule Type 32
Digna Biotech, S.L. - Pipeline Products by Mechanism of Action 33
Digna Biotech, S.L. - Recent Pipeline Updates 34
Digna Biotech, S.L. - Dormant Projects 35
Digna Biotech, S.L. - Locations And Subsidiaries 36
Head Office 36
Other Locations and Subsidiaries 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38

List of Tables
Digna Biotech, S.L., Key Information 5
Digna Biotech, S.L., Key Facts 5
Digna Biotech, S.L. - Pipeline by Indication, 2016 7
Digna Biotech, S.L. - Pipeline by Stage of Development, 2016 9
Digna Biotech, S.L. - Monotherapy Products in Pipeline, 2016 10
Digna Biotech, S.L. - Partnered Products in Pipeline, 2016 11
Digna Biotech, S.L. - Partnered Products/ Combination Treatment Modalities, 2016 12
Digna Biotech, S.L. - Phase II, 2016 13
Digna Biotech, S.L. - Phase I, 2016 14
Digna Biotech, S.L. - Preclinical, 2016 15
Digna Biotech, S.L. - Discovery, 2016 16
Digna Biotech, S.L. - Pipeline by Target, 2016 30
Digna Biotech, S.L. - Pipeline by Route of Administration, 2016 31
Digna Biotech, S.L. - Pipeline by Molecule Type, 2016 32
Digna Biotech, S.L. - Pipeline Products by Mechanism of Action, 2016 33
Digna Biotech, S.L. - Recent Pipeline Updates, 2016 34
Digna Biotech, S.L. - Dormant Developmental Projects,2016 35
Digna Biotech, S.L., Other Locations 36
Digna Biotech, S.L., Subsidiaries 36

List of Figures
Digna Biotech, S.L. - Pipeline by Top 10 Indication, 2016 7
Digna Biotech, S.L. - Pipeline by Stage of Development, 2016 9
Digna Biotech, S.L. - Monotherapy Products in Pipeline, 2016 10
Digna Biotech, S.L. - Pipeline by Target, 2016 30
Digna Biotech, S.L. - Pipeline by Route of Administration, 2016 31
Digna Biotech, S.L. - Pipeline by Molecule Type, 2016 32
Digna Biotech, S.L. - Pipeline Products by Mechanism of Action, 2016 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.